Result: One hundred seven patients were included in the study. Age ranged between 5 and 50 years. Males were 57 (53.27%); 50 (51.10%) of the females were adults and 32 (56.14%) of the males were pediatrics. The mTSE had lowered the pain level to mild in 20 (38.46%) adults, compared to 32 (58.18%) children. Twenty-eight (49.12%) males showed improvement, compared to 28 (56%) females. Post-mTSE pain score was 3.6±2.5, compared to 7.5±2.1 pre-mTSE, (p-value<0.01). The response to mTSE was more apparent in pediatrics (3.1±2.7) compared to adults (4.1±2.2), P-value=0.01. Pediatric male patients responded better to mTSE (2.8±2.6) compared to adult male patients (4.1±1.8), P-value=0.005. Conclusion: Our preliminary study reveals the efficacy of mTSE in controlling bony pain of acute painful episodes in SCD patients.